Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: Results of population pharmacokinetic modelling and Monte Carlo simulation

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 1038-1044

  Lodise, T P ^a,b,c   Nau, R ^d   Kinzig, M ^a   Drusano, G L ^c   Jones, R N ^e   Sorgel F ^a  

^a Institute for Biomedical and Pharmaceutical Research   (Germany)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e JMI LABORATORIES   (United States)

Author keywords

CSF; Gram negative bacteria; Population PK

Indexed keywords

CEFTAZIDIME; MEROPENEM;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; SURGICAL DRAINAGE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CENTRAL NERVOUS SYSTEM INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; THIENAMYCINS;

EID: 35448999380     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm325     Document Type: Article

References (39)

1. Durand ML, Calderwood SB, Weber DJ, Jr et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328: 21-8.
2. Jones ME, Draghi DC, Karlowsky JA et al. Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. Ann Clin Microbiol Antimicrob 2004; 3: 3.
3. Aronin SI. Bacterial meningitis: Principles and practical aspects of therapy. Curr Infect Dis Rep 2000; 2: 337-44.
4. Lutsar I, McCracken GH, Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998; 27: 1117-27, quiz 1128-9.
5. Lutsar I, Friedland IR. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet 2000; 39: 335-43.
6. Nau R, Sorgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet 1998; 35: 223-46.
7. Morris A, Low DE. Nosocomial bacterial meningitis, including central nervous system shunt infections. Infect Dis Clin North Am 1999; 13: 735-50.
8. Nau R, Prange HW, Kinzig M et al. Cerebrospinal fluid ceftazidime kinefics in patients with external ventriculostomies. Antimicrob Agents Chemother 1996; 40: 763-6.
9. Nau R, Lassek C, Kinzig-Schippers M et al. Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy. Antimicrob Agents Chemother 1998; 42: 2012-6.
10. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 1979; 9: 115-34.
11. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am 1999; 13: 595-618.
12. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
13. Craig, WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26 1-10, quiz 11-2.
14. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255-9.
15. Drusano GL. Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
16. Lutsar I, Ahmed A, Friedland IR et al. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-rasistant pneumococcal meningitis. Antimicrob Agents Chemother 1997; 41: 2414-7.
17. Leggett JE, Ebert S, Fantin B et al. Comparative dose - effect relations at several dosing intervals for β-lactam, aminoglycoside and quinolone antibiotics against Gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis Suppl 1990; 74: 179-84.
18. Leggett JE, Fantin B, Ebert S et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281-92.
19. Jones RN, Mendes C, Tumer PJ et al. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis 2005; 53: 247-56.
20. Rhomberg PR, Firitsche TR, Sader HS et al. Antimicrobial susceptibility pattern compansons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagn Microbiol Infect Dis 2006; 56: 57-62.
21. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component. Diagn Microbiol Infect Dis 2005; 57: 207-15.
22. Turner PJ. Use of a program-specific website to disseminate surveillance data obtained from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Study. Diagn Microbiol Infect Dis 2005; 53 273-91
23. Tumer PJ. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program. Diagn Microbiol Infect Dis 2006; 56: 341-4.
24. Turner PJ. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003). Diagn Microbiol Infect Dis 2004; 50: 291-3.
25. Turner PJ. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): A global overview. J Antimicrob Chemother 2000; 46 Suppl T2: 9-23.
26. Clinical Laboratory Standards Institute. Methods, for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Performance Standards for Antimicrobial Disk Susceptibility Tests-Seventh Edition: Approved Standard M7-A7 CLSI, Wayne, PA, USA, 2006.
27. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests-Ninth Edition: Approved Standard M-2-A9. CLSI, Wayne, PA, USA, 2006.
28. Drusano GIL, Preston SL, Gotfried MH et al. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2002; 46: 586-9.
29. Drusano GL, Preston SL, Van Guilder M et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000; 44: 2046-51.
30. Capparelli EV, Letendre SL, Ellis RJ et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 2005; 49: 2504-6.
31. Letendre SL, Capparelli EV, Ellis RJ et al. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob Agents Chemother 2000; 44: 2173-5.
32. Sable CA, Scheld WM. Theoretical and practical considerations of antibiotic therapy for bacterial meningitis. Antibiot Chemother 1992; 45: 96-117.
33. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002; 15: 95-110.
34. Decazes JM, Ernst JD, Sande MA. Correlation of in vitro time-kill curves and kinetics of bacterial killing in cerebrospinal fluid during ceftriaxone therapy of experimental Escherichia coli meningitis. Antimicrob Agents Chemother 1983; 24: 463-7.
35. Scheld WM, Sande MA. Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. J Clin Invest 1983; 71: 411-9
36. Scheld WM, Tauber MG, Zak O. et al. The influence of dosing schedules and cerebrospinal fluid bactericidal actift on the therapy of bacterial meningitis. J Antimicrob Chemother l985; 15 Suppl A: 303-12.
37. Tauber MG, Doroshow CA, Hackbarth CJ et al. Antibacterial activity of β-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. J Infect Dis 1984; 149: 568-74.
38. Tauber MG, Kunz S, Zak O et al. Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal, meningitis in rabbits. Antimicrob Agents Chemother 1989; 33: 418-23.
39. Tauber MG, Zak O, Scheld WM et al. The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits. J Infect Dis 1984; 149: 575-83.